波士顿科学退出全球心脏瓣膜业务

Core Viewpoint - Boston Scientific has announced the termination of its global sales of transcatheter aortic valve replacement (TAVR) products due to stricter regulatory requirements for new clinical trial data from various countries [1] Company Summary - Boston Scientific's TAVR valve had recently held a launch event in China just a month prior to the announcement of its exit from the market [1]